DÁIL ÉIREANN

AN BILLE SLÁINTE (EARRAÍ LIACHTA A PHRAGHSÁIL AGUS A SHOLÁTHAR), 2012
HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) BILL 2012

LEASUITHE TUARASCÁLA
REPORT AMENDMENTS

[No. 63*a* of 2012] [23 April, 2013]

[Printers Reference]

DÁIL ÉIREANN

AN BILLE SLÁINTE (EARRAÍ LIACHTA A PHRAGHSÁIL AGUS A SHOLÁTHAR), 2012
—AN TUARASCÁIL

HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) BILL 2012
—REPORT

Leasuithe
Amendments

1. In page 10, between lines 34 and 35, to insert the following:

" "non-interchangeable medicinal product" means a medicinal product which is not interchangeable with any other medicinal product for prescription purposes in the opinion of the Irish Medicines Board in accordance with the provisions of s*ection 5* of this Act;".

—Catherine Murphy.

2. In page 13, between lines 14 and 15, to insert the following:

"(2) The Board shall, as soon as is practicable after the commencement of this section, establish and publish on its Internet website, and maintain, a list (in this Act referred to as the "List of non-Interchangeable Medicinal Products"), in such form as it thinks fit, of groups of medicinal products in respect of which it is satisfied, in accordance with *section 5*, as respects each such group, that all the medicinal products which fall within the group are, for prescription purposes, not interchangeable with each other.".

—Billy Kelleher, Caoimhghín Ó Caoláin, Catherine Murphy.

3. In page 13, between lines 17 and 18, to insert the following:

"(3) The Board shall arrange for that part of its Internet website which contains the List of non-Interchangeable Medicinal Products to ordinarily be accessible by members of the public.".

—Billy Kelleher, Caoimhghín Ó Caoláin, Catherine Murphy.

4. In page 14, between lines 23 and 24, to insert the following:

"(3) The Board shall, in determining an application under *subsection (2)*, have regard to the desirability with respect to efficacy and safety of refusing to add medicinal product in the anti-epileptic drug class, used in the treatment of persons with epilepsy for the purpose of preventing seizures, to the List of Interchangeable Medicinal Products.".

—Caoimhghín Ó Caoláin, Catherine Murphy, Billy Kelleher.

5. In page 19, to delete lines 1 to 21.

—Caoimhghín Ó Caoláin.

6. In page 19, between lines 3 and 4, to insert the following:

"7.—The prescriber shall ensure that he/she prescribes in the most cost-effective manner by only writing the common or International Non-proprietary Name of the medicinal product on the prescription except where in the opinion of the prescriber it would be inappropriate to do so from a patient safety and welfare perspective.".

—Billy Kelleher, Caoimhghín Ó Caoláin.

7. In page 19, to delete lines 22 to 51.

—Caoimhghín Ó Caoláin.

8. In page 20, to delete lines 1 to 22.

—Caoimhghín Ó Caoláin.

9. In page 20, to delete lines 23 to 55 and in page 21, to delete lines 1 to 4.

—Caoimhghín Ó Caoláin.

10. In page 21, between lines 18 and 19, to insert the following:

"12.—(1) The prescriber shall detail the purpose of each medicine on the patient's prescription.

(2) The pharmacist shall include the purpose of each medicine on the label when dispensing the medicine.".

—Denis Naughten.

11. In page 21, to delete lines 21 to 28.

—Caoimhghín Ó Caoláin.

12. In page 25, line 33, after "decision" to insert the following:

"and to prescribers, pharmacists, the Irish Pharmaceutical Union and the Irish Medical Organisation".

—Billy Kelleher.

13. In page 25, line 38, after "decision" to insert the following:

"and to prescribers, pharmacists, the Irish Pharmaceutical Union and the Irish Medical Organisation".

—Billy Kelleher.

14. In page 30, lines 16 to 18, to delete all words from and including "to" where it secondly occurs in line 16 down to and including "who" in line 18.

—Caoimhghín Ó Caoláin.

15. In page 30, line 24, to delete "the branded product or".

—Caoimhghín Ó Caoláin.

16. In page 30, lines 25 to 27, to delete all words from and including "(and" in line 25 down to and including "product)" in line 27.

—Caoimhghín Ó Caoláin.

17. In page 34, between lines 4 and 5, to insert the following:

"(*b*) in section 14(1) by deleting paragraph (*f*),".

—Billy Kelleher.

18. In page 36, after line 30, to insert the following:

"37.—The Minister shall, within three months of the commencement of this Act, prepare and lay before Dáil Éireann, a report on the potential implications on patient safety and public health, in the event of medicinal products in the anti-epileptic drug class, when used in the treatment of persons with epilepsy for the purpose of preventing seizures, being determined as interchangeable medicinal products by the Board under *section 5*.".

—Billy Kelleher, Caoimhghín Ó Caoláin, Catherine Murphy.